# Progress Note 02 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Susan B. Anthony (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI014-SYN-TD
- Date: 1905-03-30
- Fictional facility: St. Posthumous Health Center
- Fictional author: Harold Pemberton, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Two-week heart failure medication safety check. **S**

## History of present illness

Miss Anthony returns two weeks after starting furosemide and empagliflozin for newly diagnosed heart failure. She is less breathless and now climbs a flight of stairs with one pause instead of two. Her ankle swelling is gone by morning and returns only slightly in the evening. Her home weights have fallen steadily by about 1.7 kg. She has had no dizziness on standing, no excess thirst, and no genital itching or urinary symptoms since starting empagliflozin. She takes every dose and keeps a weight diary. Her echocardiogram and cardiology consultation were done this morning. **S**

| Element | Detail |
|---|---|
| Interval change | Less breathless on stairs; evening ankle swelling only |
| Weight diary | Down about 1.7 kg over two weeks |
| Medication tolerance | No dizziness, thirst, or genital or urinary symptoms |
| Adherence | Every dose taken |
| NYHA class | II, improved from II to III |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No fever or fatigue beyond her usual after travel |
| Cardiovascular | Positive | Mild evening ankle swelling; no chest pain, palpitations, or orthopnea |
| Respiratory | Positive | Breathless after a flight of stairs; no cough or wheeze |
| Genitourinary | Negative | No dysuria, genital itching, or urgency |
| Neurological | Negative | No dizziness or lightheadedness on standing |

5 systems reviewed. **S**

## Current medications

- Furosemide 20 mg oral tablet, one tablet by mouth daily **S**
- Empagliflozin 10 mg oral tablet, one tablet by mouth daily **S**
- Spironolactone 25 mg oral tablet, one-half tablet (12.5 mg) by mouth daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 146/80 mmHg; pulse 78 bpm; respirations 18/min; temperature 36.6 °C; oxygen saturation 96% on room air; weight 56.8 kg; BMI 20.9 kg/m². All vital signs are synthetic.

Sodium: 137 mmol/L; Potassium: 3.9 mmol/L; Creatinine: 0.96 mg/dL; eGFR: 58 mL/min/1.73 m² (low); Glucose: 94 mg/dL; Magnesium: 1.9 mg/dL; LVEF by echocardiogram: 62%; Left atrial volume index: 42 mL/m² (high); Mitral E/e' ratio (average): 16 (high). All results are synthetic.

## Change since baseline

- Sodium: 138 mmol/L at baseline, 137 mmol/L at this visit **S**
- Potassium: 4.1 mmol/L at baseline, 3.9 mmol/L at this visit **S**
- Creatinine: 0.88 mg/dL at baseline, 0.96 mg/dL at this visit **S**
- eGFR: 64 mL/min/1.73 m² at baseline, 58 mL/min/1.73 m² (low) at this visit **S**
- Glucose: 96 mg/dL at baseline, 94 mg/dL at this visit **S**
- Magnesium: 2 mg/dL at baseline, 1.9 mg/dL at this visit **S**

## Immunizations given today

- Pneumococcal conjugate vaccine PCV20 **S**
- Respiratory syncytial virus vaccine, single dose **S**

## Physical examination

| System | Finding |
|---|---|
| General | Alert, comfortable, speaking easily |
| Neck | Jugular venous pressure 7 cm, down from 10 cm at intake |
| Lungs | Clear; the basal crackles heard at intake are gone |
| Heart | Regular rhythm; S4; no murmur |
| Extremities | Trace ankle edema, down from 2+ at intake |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Heart failure with preserved ejection fraction, improving** (I50.32). Echocardiography confirms preserved ejection fraction (62 percent) with an enlarged left atrium and raised filling pressures. She is still mildly congested, and kidney function and potassium are stable on the new medicines (eGFR 58, potassium 3.9). **S**
   - Continue furosemide 20 mg daily and empagliflozin 10 mg daily.
   - Start spironolactone 12.5 mg daily, since blood pressure is above target and potassium and kidney function are stable.
   - Repeat the basic metabolic panel in one to two weeks after starting spironolactone, by the CMID schedule.
2. **Hypertensive heart disease** (I11.0). Blood pressure 146/80 mmHg, above the 130/80 target. **S**
   - Spironolactone is expected to lower it; recheck at the three-month review.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Basic metabolic panel with magnesium | 1 to 2 weeks after starting or changing therapy; every 3 to 6 months when stable | Completed today | Two weeks after starting furosemide and empagliflozin. Sodium, potassium, creatinine, and magnesium normal; eGFR 58, a small expected fall |
| Imaging | Transthoracic echocardiogram | At diagnosis; repeat only with unexplained change | Completed today | Ejection fraction 62 percent, left atrial volume index 42 mL/m², E/e' 16: heart failure with preserved ejection fraction |
| Examination | Blood pressure, heart rate, weight, jugular venous pressure, edema, lungs | Every visit | Completed today | Weight down 1.7 kg; jugular venous pressure and edema improved |
| Survey | NYHA functional class | Every visit | Completed today | Class II |
| Survey | KCCQ-12 | Baseline, then every 3 to 6 months | Up to date | Baseline 52 at intake; next at the three-month review |
| Referral | Cardiology evaluation for specific causes | At diagnosis | Completed today | Seen today. Cardiac amyloidosis is not suspected: septal thickness 11 mm, voltage criteria for left ventricular hypertrophy on the ECG, and no carpal tunnel or neuropathy |
| Medication safety | SGLT2 inhibitor tolerance | Each visit while starting | Completed today | No volume depletion, genital infection, or urinary infection |
| Self-management | Daily weight diary | Every visit | Completed today | Reviewed; she records every morning |

## Goal progress

- Reach euvolemia with no ankle edema and a stable dry weight within three months. In progress; target 1905-06-29. **S**
- Improve the KCCQ-12 overall summary score by at least 15 points by the three-month review. In progress; target 1905-06-29. **S**
- Lower blood pressure below 130/80 by the six-month review without orthostatic symptoms. In progress; target 1905-09-28. **S**
- Resume a full speaking and travel schedule by the six-month review. In progress; target 1905-09-28. **S**

## Medication changes

- Started: Spironolactone 25 mg oral tablet, one-half tablet (12.5 mg) by mouth daily **S**

## Guideline basis

- 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure (2022), American Heart Association, American College of Cardiology, and Heart Failure Society of America
- 2023 ACC Expert Consensus Decision Pathway on Management of Heart Failure With Preserved Ejection Fraction (2023), American College of Cardiology
- CMID: Clinical Monitoring Intelligence Database, heart failure monograph (2026), Aether Forge

## Follow-up

- Basic metabolic panel in one to two weeks after starting spironolactone. Heart failure review in three months. **S**
- Next scheduled visit 1905-06-29: three-month heart failure and blood pressure review. **S**
